<h4>Background</h4>Homologous recombination deficiency (HRD) originating from inactivation of genes like BRCA1/BRCA2 is a targetable abnormality common in triple-negative breast cancer (TNBC). This evidence concerns the gene BRCA1 and hypoparathyroidism-retardation-dysmorphism syndrome.